Cancer remains one of the world’s leading health challenges, driving continuous innovation in oncology treatments. Among the most transformative breakthroughs in recent years is Chimeric Antigen Receptor (CAR) T-cell therapy, an advanced form of immunotherapy that harnesses the body’s own immune system to fight cancer. Unlike conventional treatments, CAR T-cell therapy genetically engineers a patient’s T-cells to recognize and destroy cancer cells with remarkable precision.
According to the latest MarketsandMarkets research report, the CAR T-Cell Therapy Market is projected to grow from USD 6.78 billion in 2026 to USD 13.56 billion by 2031, registering a Compound Annual Growth Rate (CAGR) of 14.9% during the forecast period. The market’s expansion is fueled by the increasing prevalence of hematologic cancers, growing investments in cellular therapies, technological advancements, and expanding regulatory approvals across major healthcare markets.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚𝐧 𝐢𝐥𝐥𝐮𝐬𝐭𝐫𝐚𝐭𝐢𝐯𝐞 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰
Rising Cancer Burden Driving CAR T-Cell Therapy Adoption
The global incidence of blood cancers such as leukemia, lymphoma, and multiple myeloma continues to increase, creating significant demand for more effective treatment options. While chemotherapy, radiation, and stem cell transplantation remain standard therapies, many patients experience relapse or become resistant to conventional treatments.
CAR T-cell therapy has emerged as a revolutionary solution for these difficult-to-treat cancers. By modifying a patient’s immune cells outside the body and reinfusing them to specifically target cancer cells, this personalized therapy has demonstrated remarkable response rates in patients with relapsed or refractory hematologic malignancies.
The growing success of commercial CAR T-cell products has encouraged healthcare providers, researchers, and pharmaceutical companies to invest heavily in expanding treatment accessibility and developing next-generation therapies targeting additional cancer types.
Technological Advancements Accelerating Market Growth
Continuous innovation remains one of the strongest drivers of the CAR T-cell therapy market. Researchers are improving manufacturing processes, reducing production timelines, and developing next-generation CAR constructs with enhanced safety and efficacy profiles.
Several advancements are contributing to market expansion, including:
- Improved gene-editing technologies
- Enhanced CAR T-cell persistence and durability
- Better management of cytokine release syndrome (CRS)
- Development of dual-target and multi-target CAR T-cell therapies
- Expansion of manufacturing capacity across treatment centers
- Growing research into allogeneic (“off-the-shelf”) CAR T-cell therapies
These innovations are expected to improve patient outcomes while reducing manufacturing complexities and treatment costs over the coming years.
Product Segment Dominated by Carvykti
Based on product, the CAR T-cell therapy market includes:
- Abecma (idecabtagene vicleucel)
- Breyanzi (lisocabtagene maraleucel)
- Carvykti (ciltacabtagene autoleucel)
- Yescarta (axicabtagene ciloleucel)
- Tecartus (brexucabtagene autoleucel)
- Kymriah (tisagenlecleucel)
- Other CAR T-cell products
Among these, Carvykti accounted for the largest market share in 2025.
Its strong market position is supported by outstanding clinical efficacy in treating relapsed or refractory multiple myeloma. Clinical studies have demonstrated deep and durable responses, making Carvykti an increasingly preferred treatment option for eligible patients.
Additionally, recent regulatory label expansions allowing earlier-line treatment, combined with increasing availability across certified treatment centers, have significantly accelerated product adoption worldwide.
B-Cell Lymphoma Represents the Largest Indication Segment
Based on indication, the market is segmented into:
- Acute Lymphoblastic Leukemia (ALL)
- Multiple Myeloma
- B-Cell Lymphoma (BCL)
- Other indications
B-Cell Lymphoma (BCL) represented the largest market share in 2025.
The segment’s dominance is primarily driven by the high prevalence of B-cell lymphomas worldwide and the strong clinical effectiveness demonstrated by CAR T-cell therapies in patients with relapsed or refractory disease.
Several approved CAR T-cell therapies have already established themselves as important treatment options for diffuse large B-cell lymphoma (DLBCL) and related malignancies, creating sustained demand across major healthcare markets.
As ongoing clinical trials evaluate CAR T-cell therapies in earlier treatment settings, the BCL segment is expected to remain one of the fastest-growing areas throughout the forecast period.
CD19 Continues to Lead Target-Based Therapies
Based on therapeutic target, the CAR T-cell therapy market is categorized into:
- CD19
- BCMA
- CD19/20
- CD7
- Other targets
The CD19 segment accounted for the highest market share in 2025.
CD19 has become one of the most successful therapeutic targets because it is consistently expressed on malignant B-cells responsible for several hematologic cancers, including leukemia and lymphoma.
Its widespread expression across numerous B-cell malignancies, combined with extensive clinical validation and multiple approved CAR T-cell therapies, has made CD19 the dominant target in the global market.
Meanwhile, BCMA-targeted therapies continue to gain momentum due to their success in treating multiple myeloma, creating additional growth opportunities for manufacturers.
North America Leads the Global CAR T-Cell Therapy Market
North America accounted for the largest share of the global CAR T-cell therapy market in 2025 and is expected to maintain its leadership throughout the forecast period.
Several factors contribute to the region’s dominance:
- Advanced healthcare infrastructure
- Early US FDA approvals for commercial CAR T-cell therapies
- Strong reimbursement frameworks
- Significant public and private investment in cell therapy research
- Presence of leading biotechnology and pharmaceutical companies
- Growing network of certified CAR T-cell treatment centers
The United States continues to be the primary growth engine, supported by ongoing clinical research, expanding manufacturing capabilities, and favorable regulatory pathways.
Meanwhile, Europe and Asia Pacific are also witnessing substantial growth as governments increase investments in advanced therapies and more hospitals gain the infrastructure required to administer CAR T-cell treatments.
Competitive Landscape
The CAR T-cell therapy market remains highly competitive, with leading pharmaceutical and biotechnology companies focusing on product innovation, clinical development, manufacturing expansion, and strategic collaborations.
Key market participants include:
- Bristol-Myers Squibb Company (US)
- Gilead Sciences, Inc. (US)
- Novartis AG (Switzerland)
- Johnson & Johnson (US)
- JW (Cayman) Therapeutics Co. Ltd (China)
These companies continue to invest heavily in expanding product portfolios, improving manufacturing efficiency, and developing next-generation CAR T-cell therapies targeting both hematologic and solid tumors.
Strategic partnerships with research institutions, biotechnology firms, and healthcare providers are also accelerating innovation while strengthening global market presence.
Future Outlook
The future of the CAR T-cell therapy market appears exceptionally promising. Continued advancements in genetic engineering, artificial intelligence-driven drug discovery, manufacturing automation, and personalized medicine are expected to transform the next generation of cell therapies.
Researchers are actively working to overcome current limitations such as manufacturing costs, treatment accessibility, toxicity management, and effectiveness against solid tumors. Successful commercialization of allogeneic CAR T-cell therapies and expanded regulatory approvals could further accelerate market growth over the next decade.
As cancer incidence continues to rise globally and demand for highly targeted therapies increases, CAR T-cell therapy is expected to become an increasingly important component of precision oncology.
Conclusion
CAR T-cell therapy has fundamentally changed the treatment landscape for hematologic cancers by delivering highly personalized and targeted immunotherapy. With growing clinical success, expanding indications, continuous technological advancements, and increasing healthcare investments, the market is entering a new phase of rapid growth.
Projected to reach USD 13.56 billion by 2031 at a CAGR of 14.9%, the global CAR T-cell therapy market offers significant opportunities for pharmaceutical companies, biotechnology innovators, healthcare providers, and investors alike. As research continues to unlock new applications and improve treatment accessibility, CAR T-cell therapy is poised to play a pivotal role in the future of cancer care.